Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Trastuzumab + XMT-2056 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 79 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
| XMT-2056 | XMT2056|XMT 2056 | HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 STING1 Agonist 21 | XMT-2056 is an antibody-drug conjugate (ADC) comprising an ERBB2 (HER2)-targeting antibody conjugated to a STING agonist, which potentially induces an anti-tumor immune response and inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 3503). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|